Kinetic study of the transformation of mefenamic acid polymorphs in various solvents and under high humidity conditions

International Journal of Pharmaceutics

Volumn 321, Issue 1-2, 2006, Pages 18-26

  Kato, Fumie ^a   Otsuka, Makoto ^b   Matsuda, Yoshihisa ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

Author keywords

Kinetic analysis; Mefenamic acid; Polymorphism; Solid state transformation

Indexed keywords

ALCOHOL; MEFENAMIC ACID; SOLVENT; WATER;

ARTICLE; COMPARATIVE STUDY; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG TRANSFORMATION; HUMIDITY; MOLECULAR STABILITY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SOLVENT EFFECT; TEMPERATURE DEPENDENCE; THREE DIMENSIONAL IMAGING; X RAY POWDER DIFFRACTION;

DRUG STABILITY; HUMIDITY; KINETICS; MEFENAMIC ACID; SOLUBILITY; SOLVENTS;

EID: 33747334411     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.04.020     Document Type: Article

References (26)

1. Aguiar A.J., and Zelmer J.E. Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid. J. Pharm. Sci. 58 (1969) 983-987
2. Airaksinen S., Luukkonen P., Jorgensen A., Karjalainen M., Rantanen J., and Yliruusi J. Effects of excipients on hydrate formation in wet masses containing theophylline. J. Pharm. Sci. 92 (2003) 516-528
3. Ashizawa K. Physico-chemical studies on the molecular details of drug crystals. Pharm. Tech. Japan 17 (2001) 1863-1874
4. Byrn S., Pfeiffer R., Ganey M., Hoiberg C., and Poochikian G. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm. Res. 12 (1995) 945-954
5. Food and Drug Administration. Guidelines: manufacturing and controls for INDs and NDAs. Pharm. Tech. Japan 1 (1985) 835-850
6. Haleblian J.K. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J. Pharm. Sci. 64 (1975) 1269-1288
7. 3. J. Am. Ceram. Soc. 55 (1972) 74-77
8. Kaneniwa N., Otsuka M., and Hayashi T. Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol. Chem. Pharm. Bull. 33 (1985) 3447-3455
9. Kokubo H., Morimoto K., Ishida T., Inoue M., and Morisaka K. Bioavailability and inhibitory effect for stress ulcer of simetidine polymorphs in rats. Int. J. Pharm. 35 (1987) 181-183
10. Kushida I., and Ahizawa K. Solid state characterization of E2101, a novel antispatic drug. J. Pharm. Sci. 91 (2002) 2193-2202
11. Matsuda Y., and Kawaguchi S. Physicochemical characterization of oxyphenbutazone and solid-state stability of its amorphous form under various temperature and humidity conditions. Chem. Pharm. Bull. 34 (1986) 1289-1298
12. Matsuda Y., and Tatsumi E. Physicochemical characterization of furosemide modifications. Int. J. Pharm. 60 (1990) 11-26
13. Otsuka M., and Matsuda Y. Polymorphism: pharmaceutical aspects. In: Swabric J., and Boylan J.C. (Eds). Encyclopedia of Pharmaceutical Technology vol. 12 (1995), Marcel Dekker, New York, NY 305-326
14. Otsuka M., Onoe M., and Matsuda Y. Physicochemical stability of phenobarbital polymorphs at various levels of humidity and temperature. Pharm. Res. 10 (1993) 577-582
15. Otsuka M., Hasegawa H., and Matsuda Y. Effect of polymorphic transformation during the extrusion-granulation process on the pharmaceutical properties of carbamazepine granules. Chem. Pharm. Bull. 45 (1997) 894-898
16. Otsuka M., Hasegawa H., and Matsuda Y. Effect of polymorphic forms of bulk powders on pharmaceutical properties of carbamazepine granules. Chem. Pharm. Bull. 47 (1999) 852-856
17. Otsuka M., Ofusa T., and Matsuda Y. Effect of environmental humidity on the transformation pathway of carbamazepine polymorphic modifications during grinding. Colloids Surf. B 13 (1999) 263-273
18. Otsuka M., Ofusa T., and Matsuda Y. Effect of binders on polymorphic transformation kinetics of carbamazepine in aqueous solution. Colloids Surf. B 17 (2000) 145-152
19. Otsuka M., Kato F., and Matsuda Y. Physicochemical stability of cimetidine amorphous forms estimated by isothermal microcalorimetry. AAPS PharmSciTech 3 (2002) article 30
20. Romero S., Escalera B., and Bustamante P. Solubility behavior of polymorphs I and II of mefenamic acid in solvent mixtures. Int. J. Pharm. 178 (1999) 193-202
21. Singh D., Marshall P.V., Shilds L., and York P. Solid-state characterization of chlordiazepoxide polymorphs. J. Pharm. Sci. 87 (1998) 655-662
22. Summer M.P., Enver R.P., and Carless J.E. The influence of crystal form on the radial stress transmission characteristics of pharmaceutical materials. J. Pharm. Pharmacol. 28 (1976) 89-99
23. Summer M.P., Enver R.P., and Carless J.E. Influence of crystal form on tensile strength of compacts of pharmaceutical materials. J. Pharm. Sci. 77 (1977) 1172-1175
24. Tang X.C., Pikal M.J., and Taylor L.S. The effect of temperature on hydrogen bonding in crystalline and amorphous phase in dihydropyrine calcium channel blockers. Pharm. Res. 19 (2002) 484-490
25. Umeda T., Ohnishi N., Yokoyama T., Kuroda T., Kita Y., Kuroda K., Tatsumi E., and Matsuda Y. A kinetic study on the isothermal transition of polymorphic forms of tolbutamide and mefenamic acid in the solid state at high temperatures. Chem. Pharm. Bull. 33 (1985) 2073-2078
26. Zhang G.Z., Gu C., Zell M.T., Burkhardt R.T., Munson E.J., and Grant D.W. Crystallization and transitions of sulfamerazine polymorphs. J. Pharm. Sci. 91 (2002) 1089-1100